Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IntReALL BCP 2020: Treatment of Childhood Relapsed Precursor B-Cell ALL
NCT07476729Phase 3Recruiting
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Sep 2026
- Primary completion
- Mar 2033
- Modality
- scFv Fragments, Monoclonal Antibodies, Bispecific Antibodies
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of inotuzumab ozogamicin and blinatumomab in B cell acute lymphoblastic leukemia (B-ALL) (4 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Event-Free Survival at 2 years, Disease-Free Survival at 2 years and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
inotuzumab ozogamicinblinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07476729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07476729.